PSAP and atherosclerosis: Integrating multi-omics technologies with live imaging to evaluate combined PSAP-targeting regimens (e.g., mTOR inhibitors with GPR37 agonists) for advanced plaque regression may pioneer new avenues for precision intervention in atherosclerosis (Figure 5).